ArticleCurrent oncology (Toronto, Ont.)2009
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
Article in Current oncology (Toronto, Ont.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients.Journal of the National Cancer Center · 2021Article
- Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2017Review
- Review
- Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?SpringerPlus · 2014Article
- Worry about cancer progression and low perceived social support: implications for quality of life among early-stage breast cancer patients.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2013Article
- Estrogen receptor testing and 10-year mortality from breast cancer: A model for determining testing strategy.Journal of pathology informatics · 2012Article
- 17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in rats.International journal of breast cancer · 2011Article
- Benefits and adverse effects of endocrine therapy.Annals of oncology : official journal of the European Society for Medical Oncology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal patients with hormone-sensitive early breast cancer are typically treated with adjuvant endocrine therapy, which significantly reduces the risk of recurrence. Because treatment is of a long duration, side effects from adjuvant therapy can be problematic. The aromatase inhibitors (AIS) are replacing tamoxifen as first-line treatment agents for early breast cancer. Here, we present the side-effect data associated with AIS in relation to bone, gynecologic, and cardiovascular health and to arthralgia and myalgia. Although AIS have been shown to decrease bone density, increase arthralgia, and affect vaginal health, these adverse events are usually manageable, and several strategies can be followed to improve quality of life in women on AI treatment. To optimize adherence to therapy. It is important that these issues are addressed so that women can benefit from treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.